Invivyd (IVVD) Projected to Post Quarterly Earnings on Thursday

Invivyd (NASDAQ:IVVD) is anticipated to post its Q2 2026 results before the market opens on Thursday, August 13th. Analysts expect Invivyd to announce earnings of ($0.15) per share and revenue of $14.4010 million for the quarter. Investors can check the company’s upcoming Q2 2026 earning report page for the latest details on the call scheduled for Wednesday, August 19, 2026 at 9:30 AM ET.

Invivyd (NASDAQ:IVVD) last released its quarterly earnings results on Thursday, May 14th. The company reported ($0.13) EPS for the quarter, missing the consensus estimate of ($0.08) by ($0.05). The company had revenue of $13.74 million for the quarter, compared to the consensus estimate of $18.04 million. Invivyd had a negative net margin of 138.90% and a negative return on equity of 53.48%. On average, analysts expect Invivyd to post $-0 EPS for the current fiscal year and $-0 EPS for the next fiscal year.

Invivyd Price Performance

Shares of Invivyd stock opened at $0.69 on Wednesday. The firm has a 50 day simple moving average of $0.80 and a 200 day simple moving average of $1.28. Invivyd has a fifty-two week low of $0.48 and a fifty-two week high of $3.07. The firm has a market cap of $202.54 million, a P/E ratio of -2.22 and a beta of 0.71.

Wall Street Analyst Weigh In

A number of research analysts have commented on IVVD shares. HC Wainwright reiterated a “buy” rating and issued a $10.00 price objective on shares of Invivyd in a research report on Monday, June 15th. Wall Street Zen downgraded Invivyd from a “hold” rating to a “strong sell” rating in a research report on Saturday, May 16th. BTIG Research reaffirmed a “buy” rating on shares of Invivyd in a research note on Tuesday, July 7th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Invivyd in a report on Friday, July 24th. Three research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, Invivyd currently has an average rating of “Hold” and an average price target of $8.00.

Institutional Trading of Invivyd

Several institutional investors and hedge funds have recently made changes to their positions in the business. RA Capital Management L.P. acquired a new stake in shares of Invivyd during the third quarter worth $18,831,000. ADAR1 Capital Management LLC acquired a new position in Invivyd in the third quarter valued at about $8,108,000. Janus Henderson Group PLC lifted its stake in Invivyd by 28.2% in the fourth quarter. Janus Henderson Group PLC now owns 32,543,142 shares of the company’s stock valued at $80,870,000 after buying an additional 7,160,065 shares during the period. State Street Corp boosted its holdings in Invivyd by 1,636.7% during the fourth quarter. State Street Corp now owns 5,637,593 shares of the company’s stock worth $13,925,000 after buying an additional 5,312,986 shares during the last quarter. Finally, Siren L.L.C. bought a new position in Invivyd during the fourth quarter worth about $9,880,000. Institutional investors own 70.36% of the company’s stock.

Invivyd Company Profile

Invivyd, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company developed INVYMAB, a platform that combines viral surveillance and predictive modeling with advanced antibody engineering. Its pipeline includes PEMGRADA (pemivibart) injection, a half-life extended investigational monoclonal antibody (mAb) for the prevention of COVID-19 in adults and adolescents; VYD2311, an mAb candidate which is in preclinical studies for the prevention or treatment for COVID-19; and adintrvimab, that is in phase 3 clinical trials for the prevention or treatment of COVID-19.